gdc
Leukemia

A Deadly Cancer Becoming a Chronic Disease

Chronic myeloid leukemia (CML) is a blood cancer that results from a genetic abnormality that causes the production of too many white blood cells in the bone marrow. However, CML is not a genetic disease that runs in families.
February 2015 Vol 1 No 1
Dana Taylor

Chronic myeloid leukemia (CML) is a blood cancer that results from a genetic abnormality that causes the production of too many white blood cells in the bone marrow. However, CML is not a genetic disease that runs in families; instead, it is caused by a change in the person’s genetic makeup for reasons that are not fully understood.

The majority of patients with CML have some genetic alternation that causes this abnormality. The National Cancer Institute estimated that 52,380 cases of CML occurred in 2014.

The New CML Drugs

In the past decade, several new drugs, called tyrosine kinase inhibitors (TKIs), have changed the face of CML from a life sentence to a chronic disease. Patients can now live long lives, as long as they continue to take their medication and don’t develop any resistance to it. The majority of TKIs are available as a pill or a capsule taken by mouth, and others are administered as an injection.

The TKIs have to be used in a specific order, with some being tried first before the doctor can prescribe a different TKI. In other cases, a patient may have side effects from one of these drugs, and the doctor will have to prescribe a different one. Each of these drugs also has different side effects. Ask your doctor to explain which of these TKIs is best for you, and why.

Cost

These new drugs are saving patients’ lives, but they are not cheap. The cost of each TKI is different, and every insurance company covers a different portion of the drug cost. Many drug companies now offer patients help with the cost of their cancer medications. Ask your care navigator to find out how much you will have to pay for the medication that is best for you, and if you need help with payments, don’t hesitate to tell your navigator.

The Symptoms of CML

CML has 3 types, or phases, called “chronic phase,” “accelerated phase,” and “blast crisis phase.” Each type of CML develops at a different pace and has different symptoms:

  1. In chronic-phase CML, patients often don’t have symptoms initially, and the disease progresses slowly.
  2. In accelerated-phase CML, the disease progresses more rapidly; its symptoms include extreme tiredness, fever, bruises, night sweats, shortness of breath, loss of appetite, unexplained weight loss, feeling of fullness/pain below the ribs on the left side, and bone pain.
  3. In the blast crisis phase, the disease progresses very fast and requires urgent treatment; its symptoms include infections, bleeding, skin changes (including bumps/tumors), swollen glands, and bone pain.
Recommended For You
Breast Cancer
Role of Biomarkers in Guiding Treatment for Breast Cancer
By Dana Taylor
Breast cancer is the second most common cancer among women, but it is important to remember that men can also have breast cancer. Recent advances in therapy have led to the discovery of specific biologic markers (biomarkers) in cancer cells, which has further led to the development of drugs known as targeted therapies.
Leukemia
Acalabrutinib-Based Triplet Shows Promise in Frontline CLL Study
The chemotherapy-free combination of venetoclax plus obinutuzumab has shown efficacy and tolerability in older patients with chronic lymphocytic leukemia. Adding acalabrutinib, a new targeted agent, may enhance the clinical benefits of this regimen, according to results of a clinical trial.
Leukemia
New Scoring System Helps Patients with CLL and Their Doctors Know When to Start Treatment
Cancer specialists are now able to use a new scoring system to decide when to start treatment for patients who have been diagnosed with chronic lymphocytic leukemia.
Leukemia
Clinical Trial Will Evaluate Novel 3-Drug Regimen for First-Line Treatment of CLL
Alliance A041702 is a large clinical trial that is exploring whether adding venetoclax to the combination of ibrutinib and obinutuzumab can improve outcomes in patients with chronic lymphocytic leukemia.
Last modified: October 5, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country